✦ LIBER ✦

IMPROVEMENT IN IRON STATUS AND LIVER FUNCTION IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD WITH LONG-TERM SUBCUTANEOUS DESFERRIOXAMINE

✍ Scribed by Hoffbrand, A.V.; Gorman, A.; Laulicht, M.; Garidi, M.; Economidou, J.; Georgipoulou, P.; Hussain, M.A.M.; Flynn, D.M.

Book ID: 123127673
Publisher: The Lancet
Year: 1979
Tongue: English
Weight: 346 KB
Volume: 313
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(79)91721-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SUBCUTANEOUS INFUSION AND INTRAMUSCULAR

SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD

✍ HUSSAIN, M 📂 Article 📅 1976 🏛 The Lancet 🌐 English ⚖ 406 KB

Listeriosis in patients with long-term h

Listeriosis in patients with long-term hemodialysis and transfusional iron overload

✍ Robert T. Mossey; James Sondheimer 📂 Article 📅 1985 🏛 Elsevier Science 🌐 English ⚖ 415 KB

Combined therapy with desferrioxamine an

Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload

✍ S. Daar; A. V. Pathare 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 102 KB

DESFERRIOXAMINE TO IMPROVE CARDIAC FUNCT

DESFERRIOXAMINE TO IMPROVE CARDIAC FUNCTION IN IRON-OVERLOADED PATIENTS WITH THALASSAEMIA MAJOR

✍ Marcus, R.E.; Davies, SallyC.; Bantock, H.M.; Underwood, S.R.; Walton, S.; Huehn 📂 Article 📅 1984 🏛 The Lancet 🌐 English ⚖ 329 KB

Reduction in Liver Iron in Hemodialysis

Reduction in Liver Iron in Hemodialysis Patients With Transfusional Iron Overload by Deferoxamine Mesylate

✍ Mossey, Robert T.; Wielopolski, Lucien; Bellucci, Alessandro G.; Wilkes, Barry M 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 506 KB

Intravenous and subcutaneous desferrioxa

Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload

✍ G. E. Janka; P. Möhring; M. Helmig; R. J. Haas; K. Betke 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 430 KB

Ten children with transfusion dependent anemias (thalassemia, sideroblastic anemia, congenital pure red cell aplasia) received either intravenous desferrioxamine (DF) in increasing doses up to 450 mg/kg at the time of transfusion or daily subcutaneous DF up to ll0mg/kg on an outpatient basis. No pat